?Effect of Allicin derivatives capsule in treatment of patients with new Coronavirus

Comparing the efficacy of Allicin derivatives capsule and Placebo as an adjuvant for patients with COVID-19: A double-blind randomized placebo controlled clinical trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200610047722N1

Enrollment

Registered

2020-07-07

Start date

2020-06-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COVID-19. Condition 2: COVID-19. COVID-19, virus not identified COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Standard treatment for COVID-19 plus Allicin derivatives capsule (90 mg) twice per day for 14 days. Intervention 2: Control group: Standard treatment for COVID-19 p

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with RT-PCR positive for SARS-CoV-2 , clinical sign and symptoms (fever, cough and myalgia) and CT scan indicate COVID-19 positive. Age 18-70 Sign consent form

Exclusion criteria

Exclusion criteria: History of allergic reaction to Allicin History of allergic reaction to Garlic or Onion History of low blood pressure or gastrointestinal tract bleeding Low blood pressure and the beginning of study (lower that 120/80 mmHg) Patients with immune deficiency disorders (patients undergo chemotherapy, organ or bone marrow transplants and patients with autoimmune disease) No need to use ventilator during the study Unable to swallow the oral medication Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Body temperature. Timepoint: Before starting the study and every day during the study. Method of measurement: Thermometer.;O2 saturation. Timepoint: Before starting the study and every day during the study. Method of measurement: pulse oximeter.;Time to recovery. Timepoint: Everyday until the full recovery. Method of measurement: WHO criteria for COVID-19.	—

Secondary

Measure	Time frame
Lymphocytopenia. Timepoint: Before starting the study, one week and two week later. Method of measurement: Cell Counter (CBC).;C-reactive protein. Timepoint: Before starting the study, one week and two week later. Method of measurement: C-RP kit.;Serious side effects. Timepoint: Before starting the study and everyday during the study. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Masoud Hashemian

Mashhad University of Medical Sciences

hashemianam@mums.ac.ir+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026